Novavax (NVAX) Competitors $6.41 +0.55 (+9.39%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NVAX vs. FOLD, LGND, DVAX, MNKD, BCRX, INVA, OPK, CLDX, GERN, and MYGNShould you be buying Novavax stock or one of its competitors? The main competitors of Novavax include Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Dynavax Technologies (DVAX), MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), OPKO Health (OPK), Celldex Therapeutics (CLDX), Geron (GERN), and Myriad Genetics (MYGN). These companies are all part of the "biotechnology" industry. Novavax vs. Amicus Therapeutics Ligand Pharmaceuticals Dynavax Technologies MannKind BioCryst Pharmaceuticals Innoviva OPKO Health Celldex Therapeutics Geron Myriad Genetics Amicus Therapeutics (NASDAQ:FOLD) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations. Which has more volatility & risk, FOLD or NVAX? Amicus Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Novavax has a beta of 3.15, suggesting that its stock price is 215% more volatile than the S&P 500. Does the MarketBeat Community favor FOLD or NVAX? Novavax received 319 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. Likewise, 74.06% of users gave Novavax an outperform vote while only 72.98% of users gave Amicus Therapeutics an outperform vote. CompanyUnderperformOutperformAmicus TherapeuticsOutperform Votes53272.98% Underperform Votes19727.02% NovavaxOutperform Votes85174.06% Underperform Votes29825.94% Do analysts prefer FOLD or NVAX? Amicus Therapeutics presently has a consensus target price of $16.75, indicating a potential upside of 149.26%. Novavax has a consensus target price of $18.00, indicating a potential upside of 180.81%. Given Novavax's higher possible upside, analysts clearly believe Novavax is more favorable than Amicus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amicus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Novavax 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Is FOLD or NVAX more profitable? Amicus Therapeutics has a net margin of -10.62% compared to Novavax's net margin of -32.18%. Amicus Therapeutics' return on equity of 12.44% beat Novavax's return on equity.Company Net Margins Return on Equity Return on Assets Amicus Therapeutics-10.62% 12.44% 2.60% Novavax -32.18%N/A -17.05% Which has preferable earnings & valuation, FOLD or NVAX? Amicus Therapeutics has higher earnings, but lower revenue than Novavax. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmicus Therapeutics$528.30M3.91-$151.58M-$0.18-37.33Novavax$682.16M1.51-$545.06M-$1.33-4.82 Does the media favor FOLD or NVAX? In the previous week, Novavax had 9 more articles in the media than Amicus Therapeutics. MarketBeat recorded 21 mentions for Novavax and 12 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.04 beat Novavax's score of 0.59 indicating that Amicus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amicus Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 8 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in FOLD or NVAX? 53.0% of Novavax shares are held by institutional investors. 2.2% of Amicus Therapeutics shares are held by company insiders. Comparatively, 1.0% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryAmicus Therapeutics beats Novavax on 10 of the 18 factors compared between the two stocks. Remove Ads Get Novavax News Delivered to You Automatically Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVAX vs. The Competition Export to ExcelMetricNovavaxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.03B$2.90B$5.35B$7.58BDividend YieldN/A1.91%5.11%4.33%P/E Ratio-2.8430.3721.6517.79Price / Sales1.51438.12375.8994.27Price / CashN/A168.6838.1534.64Price / Book-1.063.456.443.99Net Income-$545.06M-$72.06M$3.20B$247.24M7 Day Performance-1.99%4.37%6.67%5.84%1 Month Performance-19.77%-17.35%-6.27%-5.78%1 Year Performance49.77%-31.05%8.56%-1.99% Novavax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVAXNovavax3.5987 of 5 stars$6.41+9.4%$18.00+180.8%+36.9%$1.03B$682.16M-2.841,990Gap UpFOLDAmicus Therapeutics3.9213 of 5 stars$7.08-5.7%$16.75+136.7%-39.3%$2.17B$528.30M-39.31480Positive NewsGap UpLGNDLigand Pharmaceuticals4.3403 of 5 stars$99.41-0.2%$147.00+47.9%+28.2%$1.91B$167.13M39.4880Positive NewsDVAXDynavax Technologies4.2755 of 5 stars$12.49-1.3%$21.50+72.2%-5.0%$1.55B$277.25M69.23350Positive NewsGap DownMNKDMannKind1.9923 of 5 stars$4.66-1.8%$9.21+97.9%+12.3%$1.41B$285.50M66.36400News CoveragePositive NewsGap DownBCRXBioCryst Pharmaceuticals4.1122 of 5 stars$6.69-2.0%$15.57+132.7%+43.0%$1.40B$450.71M-10.97530Analyst ForecastGap DownINVAInnoviva4.3332 of 5 stars$17.38-1.9%$55.00+216.5%+19.8%$1.09B$358.71M25.17100Positive NewsGap DownOPKOPKO Health4.0144 of 5 stars$1.53-1.6%$2.75+80.3%+15.0%$1.02B$713.14M-8.033,930Gap DownCLDXCelldex Therapeutics2.268 of 5 stars$15.47-2.0%$54.33+251.2%-57.1%$1.02B$7.02M-5.97150News CoveragePositive NewsGap UpGERNGeron3.7602 of 5 stars$1.38-0.4%$5.75+318.2%-62.1%$875.74M$76.99M-4.3070Short Interest ↑Gap DownMYGNMyriad Genetics3.8037 of 5 stars$8.06-0.9%$20.89+159.3%-59.1%$733.03M$837.60M-6.182,700Gap Down Remove Ads Related Companies and Tools Related Companies Amicus Therapeutics Alternatives Ligand Pharmaceuticals Alternatives Dynavax Technologies Alternatives MannKind Alternatives BioCryst Pharmaceuticals Alternatives Innoviva Alternatives OPKO Health Alternatives Celldex Therapeutics Alternatives Geron Alternatives Myriad Genetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVAX) was last updated on 4/14/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novavax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NVAX Stock Free NVAX Stock Alerts